Piracetam in the treatment of schizophrenia: Implications for the glutamate hypothesis of schizophrenia

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 5, 1999, Pages 369-374

  Noorbala, A A ^a   Akhondzadeh, S ^a,b   Davari Ashtiani, R ^a   Amini Nooshabadi, H ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR; HALOPERIDOL; NOOTROPIC AGENT; PIRACETAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; MALE; NOOTROPIC AGENTS; PIRACETAM; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0032708893     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00238.x     Document Type: Article

References (45)

1. 1. Jablensky A, Sartorius N, Ernberg G. (1991) Schizophrenia: manifestation, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine, 20(Suppl.), 1-97.
2. 2. Akhondzadeh S. (1998) The glutamate hypothesis of schizophrenia. Journal of Clinical Pharmacy and Therapeutics, 23, 243-246.
3. 3. Anderson NC, Olsen SA. (1982) Negative vs. positive schizophrenia. Definition and Validation Archives of General Psychiatry, 39, 789-794.
4. 4. Arndt S, Allinger RJ, Anderson NC. (1991) The distinction of positive and negative symptoms. The failure of a two dimensional model. British Journal of Psychiatry, 158, 317-322.
5. 5. Baron M, Gruen R, Rainer JD. (1985) A family study of schizophrenic and normal control probands: implications for the spectrum concept of schizophrenia. American Journal of Psychiatry, 142, 447-455.
6. 6. Kendler K, Diehl SR. (1993) The genetics of schizophrenia: a current genetic-epidemiologic perspective. Schizophrenia Bulletin, 19, 261-285.
7. 7. Heyman I, Murray RM. (1992) Schizophrenia and neuro-development. Journal of the Royal College of Physicians, London, 26, 143-146.
8. 8. Bogerts B. (1993) Recent advances in the neuropathology of schizophrenia. Schizophrenia Bulletin, 19, 431-445.
9. 9. Deniker P. (1970) Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd F, Blackwell B, eds. Discoveries in Biological Psychiatry. Philadelphia: J. B. Lippincott, Company, 155-164.
10. 10. Snyder S. (1976) The dopamine hypothesis in schizophrenia: focus on the dopamine receptor. American Journal of Psychiatry, 133, 197-202.
11. 11. Angrist B, Rotrosen J, Gershon S. (1980) Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology, 72, 17-19.
12. 12. Seiden L, Sabol K. (1993) Amphetamine: effects on catecholamine systems and behavior. Annals of Review of Pharmacology and Toxicology, 32, 639-677.
13. 13. Johnstone E, Crow T, Frith C. (1978) Mechanism of antipsychotic effect in the treatment of acute schizophrenia. Lancet, I, 848-851.
14. 14. Meltzer HY, Lee MA, Ranjan R. (1994) Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatrica Scandinavica, 90 (Suppl. 384), 95-101.
15. 15. Meltzer HY, Sommers AA. (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. Journal of Clinical Psychopharmacology, 6, 329-338.
16. 16. Morrison RL, Bellack AS. (1987) Social functioning of schizophrenic patients: clinical and research issues. Schizophrenia Bulletin, 13, 715-725.
17. 17. Grace AA. (1991) Phasic nervous tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience, 41, 1-24.
18. 18. Atmminga CA, Cascella N, Fakouhi TD, Herting RL. (1992) Enhancement of NMDA-mediated transmission in schizophrenia. Effects of milacemide. In: Meltzer HY, ed. Novel Antipsychotic Drugs. New York: Raven Press, 171-177.
19. 19. Kim JS, Kornhber HH, Schmid-Burgk W, Holzmuller B. (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neuroscience Letters, 20, 379-382.
20. 20. Fonnum F. (1984) Glutamate: a neurotransmitter in mammalian brain. Journal of Neurochemistry, 42, 1-11.
21. 21. Collingridge GL, Lester R. (1989) Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacology Review, 40, 143-210.
22. 22. Monaghan DT, Bridges RJ, Cotman CW. (1989) The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annual Review of Pharmacology and Toxicology, 29, 365-402.
23. 23. Nakanishi S. (1992) Molecular diversity of glutamate receptors and implication for brain function. Science, 258, 597-603.
24. 24. Miller RJ. (1991) Metabotropic excitatory amino acid receptors reveal their true colors. Trends in Pharmacological Science, 12, 365-367.
25. 25. Drejer J, Larsson OM, Schoesbou A. (1982) Characterization of L-glutamate uptake into and release from astrocytes and neurons cultured from different brain regions. Experimental Brain Research, 47, 259-269.
26. 26. Lodge D, Johnson KM. (1990) Non-competitive excitatory amino acid receptor antagonists. Trends in Pharmacological Science, 11, 81-88.
27. 27. Copani A, Genazzani AA, Aleppo G, et al. (1992) Nootropic drugs positively modulate alpha-arnino-3-hydroxy-5-methyl-4-isoxazolpropionic acid-sensitive glutamate receptors in neuronal cultures. Journal of Neurochemistry, 54, 1199-1204.
28. 28. Cohen SA, Muller WE. (1993) Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. Pharmacology, 47, 217-222.
29. 29. Gouliaev AH, Senning A. (1994) Piracetam and other structurally related nootropics. Brain Research Reviews, 19, 180-222.
30. 30. American Psychiatric Association. (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM IV) 4th edn. American Psychiatric Press, Washington, DC.
31. 31. Kay SR, Fiszbein A, Opler LA. (1987) The positive and negative syndrome scale for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
32. 32. Javitt DC, Zukin SR. (1991) Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148, 1301-1308.
33. 33. Krystal JH, Karper LP, Sebyl JP, et al. (1994) Subanesthetic effects of noncompetitive NMDA antagonist, Ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51, 199-214.
34. 34. Moghaddam B. (1994) Recent basic findings in support of excitatory amino acid hypothesis of schizophrenia. Progress in Neuro-Psychopharmacalogical and Biological Psychiatry, 18, 859-870.
35. 35. Ishimaru MJ, Toru M. (1977) The glutamate hypothesis of schizophrenia. CNS Drugs, 7, 47-67.
36. 36. Toru M, Kurumaji A, Ishimaru M. (1994) Excitatory aminiacids: implications for psychiatric disorder research. Life Science, 22, 1683-1699.
37. 37. Olney JW, Farber NB. (1995) Glutamate receptor dysfunction and schizophrenia. Archive of General Psychiatry, 52. 998-1007.
38. 38. Harrison PJ, McLaghlin D, Kerwin RW. (1991) Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet, 337, 450-452.
39. 39. Ulas J, Cotman C. (1993) Excitatory amino acid receptors in schizophrenia. Schizophrenia Bulletin, 19, 105-117.
40. 40. Akhondzadeh S, Mohammadi MR, Amini-Noshabadi H, Davari-Ashtiani R. (1999) Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. Journal of Clinical Pharmacy and Therapeutics, 23, 49-52.
41. 41. Farber NB, Kim SH, Olney JW. (1997) Costimulation of muscarinic and non-NMDA glutamate receptors reproduces NMDA antagonist neurotoxicity. Society of Neuroscience, 23, 2308.
42. 42. Kim SH, Farber NB, Price MT, Olney JW. (1997) Clonidine suppresses MK801-induced acetylcholoine release in rat posterior cingulate coetex: in vivo, micodialysis study. Society of Neuroscience, 23, 2308.
43. 43. Olney JW, Labruyere J, Wang C, Wozniak DF, Price MT, Sesma MA. (1991) NMDA antagonist neurotoxicity: mechanism and prevention. Science, 254, 1515-1518.
44. 44. Sharp JW, Peterson DL, Langford MT. (1995) DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp 70 heat shock gene in the rat cingulate and retrisplenial cortex. Brain Research, 687, 114-124.
45. 45. Thomas JW, Hood WF, Monahan JB, Contreras PC, O'Donohue TL. (1988) Glycine modulation of phencyclidine binding site in mammalian brain. Brain Research, 442, 396-398.